Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
OMERthis companyOmeros Corporation	$17.52	-326×	-9×	0×	-720.85×	-117.8%	0.0%	0.0%	0.0%	2.8%	-45.3%	-10.6%	-1.97×	-125.26×	0×	2.76×	0.0%	6	0.2	2	C+
ANABAnaptysBio, Inc.	$47.82	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
BHVNBiohaven Ltd.	$15.18	-1.65×	23.33×	0×	-1.75×	-103.9%	0.0%	0.0%	0.0%	-1418.8%	-218.4%	-50.2%	5.47×	-0.08×	0×	3.18×	0.0%	3	-15.51	2	C
CGEMCullinan Therapeutics, Inc.	$11.61	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
CRVSCorvus Pharmaceuticals, Inc.	$11.10	-40.53×	9.93×	0×	-39.82×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-69.1%	-5.4%	0.02×	0.24×	0×	6.21×	0.0%	2	32.84	2	C
MGNXMacroGenics, Inc.	$2.44	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
Peer median	—	-2.78×	9.93×	0×	-2.39×	-103.9%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.38×	-0.08×	0×	6.21×	0.0%	2	2.21	2	—